Experience of using prolgolimab in real clinical practice

Authors: Protsenko S.A¹, Imyanitov E.N¹^,2, Malygin A.Y.¹, Yurlov D.O¹, Semenova A.I¹, Latipova D.K.¹, Novik A.V¹^,2, Teletaeva G.M¹, Zinoviev G.V¹, Ebert M.A¹^,2, Artemieva A.S¹, Baldueva I.A¹
Affiliations:
1. N.N. Petrov National Medical Research Center of Oncology
2. Saint Petersburg State Pediatric Medical University
Issue: Vol 28, No 7 (2021)
Pages: 51-55
Section: Articles
URL: https://journals.eco-vector.com/2073-4034/article/view/313178
DOI: https://doi.org/10.18565/pharmateca.2021.7.51-55
ID: 313178

Cite item

Full Text

Open Access

Open Access
Restricted Access

Restricted Access

Access granted
Restricted Access

Restricted Access

Subscription or Fee Access

Abstract
Full Text
About the authors
References
Supplementary files
Statistics

Abstract

Melanoma of the skin is one of the most aggressive malignant neoplasms. Approaches to the treatment of metastatic skin melanoma have been dynamically developing over the past decade. The first original IgG1 anti-PD-lmonoclonal antibody containing the Fc-silencing ‘LALA’ mutation has been developed in Russia. This article demonstrates our own experience of using the domestic PD-1 inhibitor prolgolimab in clinical practice.

Keywords

neoadjuvant immunotherapy, immuno-oncology, PD-1 inhibitors, prolgolimab

Full Text

Restricted Access

About the authors

S. A Protsenko

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

E. N Imyanitov

N.N. Petrov National Medical Research Center of Oncology; Saint Petersburg State Pediatric Medical University

St. Petersburg, Russia

A. Yu Malygin

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

D. O Yurlov

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

A. I Semenova

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

D. Kh Latipova

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

A. V Novik

N.N. Petrov National Medical Research Center of Oncology; Saint Petersburg State Pediatric Medical University

St. Petersburg, Russia

G. M Teletaeva

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

G. V Zinoviev

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

M. A Ebert

N.N. Petrov National Medical Research Center of Oncology; Saint Petersburg State Pediatric Medical University

St. Petersburg, Russia

A. S Artemieva

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

I. A Baldueva

N.N. Petrov National Medical Research Center of Oncology

St. Petersburg, Russia

References

Tjulandin S., Fedyanin M., Semiglazova T., et al. BCD-100 - first Russian PD-1 inhibitor. J Mod Oncol. 2017;19:13-20.
Tjulandin S., et al. Novel PD-1 inhibitor prolgolimab: expanding non-resectable/metastatic melanoma therapy choice. Eur J Cancer. 2021;149:222-32. doi: 10.1016/j.ejca.2021.02.030.
Rozeman E.A., et al. Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma. Nat Med. 2021; 27(2):256-63. doi: 10.1038/s41591-020- 01211-7
Blank C.U., Reijers I.L.M., Pennington T., et al. First safety and efficacy results of PRADO: A phase II study of personalized response-driven surgery and adjuvant therapy after neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in resectable stage III melanoma. J Clin Oncol. 2020;38;15S. URL: https://meetinglibrary.asco.org/record/185836/ abstract
Krishnamoorthy M., Lenehan J.G., Vareki S.M. Neoadjuvant Immunotherapy for High-Risk, Resectable Malignancies: Scientific Rationale and Clinical Challenges, JNCI: J Nation Cancer Inst. 2021, djaa216. doi: 10.1093/jnci/djaa216. 7-y
Huang A.C., et al.Asingledose ofneoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. Nat. Med. 2019;25(3):454-61. doi: 10.1038/s41591-019-0357-y

Supplementary files

Supplementary Files

Action

1. JATS XML

Copyright (c) 2021 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies

TOP